Eurartesim: new combination malaria treatment

Eurartesim, a fixed-dose combination of piperaquine and dihydroartemisinin, is now available for the treatment of uncomplicated Plasmodium falciparum malaria in adults and children over 6 months.

The combination treatment includes piperaquine, which has good activity against chloroquine-resistant Plasmodium strains in vitro
The combination treatment includes piperaquine, which has good activity against chloroquine-resistant Plasmodium strains in vitro

PHARMACOLOGY

Eurartesim is a combination of the bisquinolone, piperaquine, and dihydroartemisinin, the active metabolite of all artemisinin derivatives. The mechanism of action of piperaquine is unknown, but it is likely to act in a similar way to chloroquine, which prevents haem detoxification within the malaria parasite. Dihydroartemisinin has an endoperoxide bridge that is thought to be essential for its function, causing free-radical damage to parasite membranes.1

CLINICAL STUDIES

The efficacy of the piperaquine/dihydroartemisinin combination for the treatment of uncomplicated P. falciparum malaria was assessed in two randomised, open-label trials. The first study (n=1089) compared the combination with artesunate/mefloquine in adults and children in Asia,2 whereas the second study (n=1524) compared it with artemether/lumefantrine in children in Africa.3

Intention-to-treat analysis showed that 87.9% of patients treated with piperaquine/dihydroartemisinin were cured at day 63 in the Asian study, and 90.4% were cured at day 28 in the African study.

In both studies, the piperaquine/dihydroartemisinin combination was non-inferior to the comparator treatment, and had a similar safety profile.2,3 However, QT prolongation was observed more frequently and to a larger extent in patients receiving piperaquine/dihydroartemisinin than among those given the comparator treatments.1

References:

  1. Eurartesim Summary of Product Characteristics, October 2011.
  2. Valecha N et al. PLoS ONE 2010; 5: e11880.
  3. Bassat Q et al. PLoS ONE 2009; 4: e7871.


View Eurartesim drug record
 
Further information: sigma-tau

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more